The National Institute of Neurological Disorders and Stroke, which is a National Institutes of Health affiliate, recently awarded researchers from St. Jude Children’s Research Hospital and Washington University in St. Louis a $3.1 million grant.
Tanja Mittag, of the Department of Structural Biology at St. Jude and Washington University’s Rohit Pappu, who is an engineering professor in the McKelvey School of Engineering, collected the funds, which would enable the team to research RNA-binding proteins that mutate in individuals with genetic forms of Lou Gehrig’s disease, also referred to as amyotrophic lateral sclerosis.
The objective is to discover the basic process that results in the formation of inclusions of RNA-binding proteins and allow future identification of novel ALS treatments and other neurodegenerative ailments.
Pappu stated that this was an opportunity to collaborate and build upon work that had been launched by the St. Jude Research Collaborative. He explained that the researchers would be focused on central features of stress granules and the effect of ALS-related mutations on various facets of pathology that have been linked to proteins’ dynamic arrest in stress granules, adding that the ability to adjust these dynamics would be a new therapeutic strategy useful in ALS as well as other neurodegenerative diseases.
This research that will be funded by the grant will be adding on to prior St. Jude–Washington University partnership work, which found that the liquid-liquid phase separation of RNA-binding proteins led to formation of stress granules in cells. Mittag explained that while they found that phase separation promoted solid protein aggregate formation, they did not understand why. Mittag added that their new research looking into the underlying mechanisms would help direct the development of novel therapeutics in the future.
The research that resulted in this grant being awarded had been financed by the St. Jude Research Collaborative. This program featured researchers from Princeton University, St. Jude and Washington University in St. Louis, to help speed up progress in the field. This is 1 of the 5 collaboratives by St. Jude that have been developed to unite researchers from leading research programs around the globe, in an attempt to address the unknown.
The St. Jude Research Collaboratives are tackling various gaps in knowledge for noncancerous hematological ailments, pediatric cancers and other potentially fatal childhood disorders, with the objective being to accelerate advances in these fields.
Charles Roberts, the collaborative’s administrative leader, who is also the St. Jude Comprehensive Cancer Center director and executive president, stated that when it came to solving complex challenges, collaboration was the key to innovation.
Collaboration is also a cornerstone in the work RYAH Group Inc. is engaged in. For example, the company has a platform called RYAH MD, which helps patients to collaborate with their doctors on issues such as determining the dosage of medical marijuana products one should take as well as facilitating video calls between doctors and their patients.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…
Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months…